VU0364572 

VU0364572 is a selective allosteric agonist of the M1 muscarinic receptor with an EC₅₀ of 0.11 μM. VU0364572 has neuroprotective potential for preventing memory impairments and reducing neuropathology in Alzheimer’s Disease. VU0364572 is orally active and is CNS penetrant^[1][3].

VU0364572 (30 μM; 25 min) promotes KCNQ2, NR1 and MARCKS phosphorylation in striatal/NAc slices^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

VU0364572 (10 mg/kg/day; oral; 4 months) shows neuroprotective effects in 5XFAD transgenic Alzheimer’s mice. VU0364572 has a half life of 45 minutes^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

373.49

C₂₁H₃₁N₃O₃

1240514-87-7

O=C(N1CCC(N2C[C@H](NC(C3=CC=CC=C3C)=O)CCC2)CC1)OCC

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Lebois EP, et al. Disease-Modifying Effects of M1 Muscarinic Acetylcholine Receptor Activation in an Alzheimer's Disease Mouse Model. ACS Chem Neurosci. 2017 Jun 21;8(6):1177-1187.  [Content Brief]

  [2]. Faruk MO, et al. Muscarinic signaling regulates voltage-gated potassium channel KCNQ2 phosphorylation in the nucleus accumbens via protein kinase C for aversive learning. J Neurochem. 2022 Feb;160(3):325-341.  [Content Brief]

  [3]. Lebois EP, et al. Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071. Bioorg Med Chem Lett. 2011 Nov 1;21(21):6451-5.  [Content Brief]